A small clinical trial of 10 patients with early Alzheimer’s disease has shown that the memory loss and cognitive impairment can be reversed.
Not only were improvements sustained, but some patients returned to work, regained their ability to speak different languages, and showed an increase in brain matter volume after just a few months.
“All of these patients had either well-defined mild cognitive impairment, subjective cognitive impairment, or had been diagnosed with Alzheimer’s disease before beginning the program,” says one of the team, Dale Bredesen, University of California, Los Angeles. “Follow up testing showed some of the patients going from abnormal to normal.”
The study investigated the effects of a new kind of personalised treatment on the cognitive abilities of 10 patients who were experiencing age-related decline.
The treatment – called metabolic enhancement for neurodegeneration, or MEND – is based on 36 different factors, including changes in diet, exercise, and sleeping habits, plus the integration of certain drugs, vitamins, and brain stimulation therapy to their regular routine.
These lifestyle changes and treatments were sustained for five to 24 months, and the team from UCLA and the Buck Institute for Research on Ageing in California reports that many of the patients showed real, life-altering improvements as a result.
According to the researchers, this is the first study to objectively show that memory loss in patients can be reversed, and improvement sustained.
“The magnitude of improvement in these 10 patients is unprecedented, providing additional objective evidence that this programmatic approach to cognitive decline is highly effective,” says Bredesen.
Publishing their results in the journal Aging, the team hasn’t gone into much detail about how MEND works, probably because each treatment involves a complex combination of factors that has been specifically designed to treat just one individual, as each person’s version of Alzheimer’s appears to be different.
But they do mention something that all but one of the patients have in common – they are all at genetic risk for Alzheimer’s disease, carrying at least one copy of the APOE4 allele. Five of the patients are carrying two copies of APOE4, which gives them a 10- to 12-fold increased risk of developing the disease, the team explains.
This means there could be some benefit in getting tested for this genetic risk, because patients might finally be able to do something to stall the progression of the disease. Around 65 percent of Alzheimer’s cases in the US involve APOE4.
“We’re entering a new era,” says Bredesen. “The old advice was to avoid testing for APOE because there was nothing that could be done about it. Now we’re recommending that people find out their genetic status as early as possible so they can go on prevention.”
The Latest on: APOE4
via Google News
The Latest on: APOE4
- Is a Woman’s Brain More Susceptible to Tau Pathology? on February 8, 2019 at 2:46 pm
This sex difference was slightly more pronounced in ApoE4 carriers. It is unclear if women are more susceptible or more resilient to tau than men. But what does this mean? That tau accumulates faster ... […]
- In Alzheimer’s, Too Little REST Spurs Too Much Neurogenesis on February 4, 2019 at 1:49 pm
Without it, neural differentiation accelerates, prematurely depleting the stem cell pool. ApoE4 alone mimics this phenotype. What’s more, the same phenotype arises in progenitor cells engineered to ex... […]
- Biogen's BAN2401 Not A Home Run Anymore, But Still Holds Some Promise on December 23, 2018 at 10:16 am
Detailing The ApoE4 and Dose Response Debate for BAN2401 After reporting limited but exciting top-line data from its phase 2 trial with BAN2401 in early July (which I detailed here), Biogen then relea... […]
- Experimental Alzheimer’s drug A03 improves memory in mice on December 21, 2018 at 7:56 am
The mice were genetically modified to have a protein called ApoE4, the most common genetic risk factor for Alzheimer’s disease in humans that has been linked to some forms of the disease. More than 10 ... […]
- Vaccine or drug for late-onset Alzheimer's could be on the way on December 18, 2018 at 3:32 am
There are three major forms of ApoE (i.e., ApoE2, ApoE3, and ApoE4); individuals who carry ApoE4 are up to 10 times more likely to develop Alzheimer's than those with ApoE2 and ApoE3 forms. ApoE4 prom... […]
- Chronic inflammation with ApoE4 gene results in increased risk of Alzheimer’s, BUSM researchers say on October 25, 2018 at 5:59 pm
The Boston University School of Medicine. A new study by researchers at the school suggests treating chronic inflammation in elderly people could help avert the onset of Alzheimer’s disease. BRIAN SON... […]
- Chronic Inflammation May Boost Genetic Risk of Alzheimer’s on October 21, 2018 at 8:20 am
While having the ApoE4 gene is a major genetic risk factor for Alzheimer’s disease (AD), not all ApoE4 carriers develop the disease. But new research shows that ApoE4 coupled with chronic inflammation ... […]
- Study clarifies protein’s role in dementia on September 20, 2018 at 10:24 am
This technology enabled investigators to analyze blood flow in areas deep in the substance of the brain, where ApoE4 promotes damage implicated in vascular dementia and Alzheimer’s disease. A protein ... […]
- Study clarifies ApoE4's role in dementia on September 20, 2018 at 7:50 am
ApoE4, a protein linked to both Alzheimer's disease and a form of dementia caused by damage of blood vessels in the brain, increases the risk of cognitive impairment by reducing the number and respons... […]
- Alzheimer's gene neutralised in human brain for first time on April 10, 2018 at 7:36 am
Having one copy of the apoE4 gene more than doubles a person's likelihood of developing Alzheimer's disease, and having two copies of the gene increases the risk by 12-fold, as compared to the most co... […]
via Bing News